JP2023516458A - ヒト細胞由来細胞外小胞を含有する噴霧吸入製剤、その調製方法及び使用 - Google Patents

ヒト細胞由来細胞外小胞を含有する噴霧吸入製剤、その調製方法及び使用 Download PDF

Info

Publication number
JP2023516458A
JP2023516458A JP2022554328A JP2022554328A JP2023516458A JP 2023516458 A JP2023516458 A JP 2023516458A JP 2022554328 A JP2022554328 A JP 2022554328A JP 2022554328 A JP2022554328 A JP 2022554328A JP 2023516458 A JP2023516458 A JP 2023516458A
Authority
JP
Japan
Prior art keywords
cells
extracellular vesicles
pharmaceutical composition
human
injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022554328A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023516458A5 (https=
JPWO2021180237A5 (https=
Inventor
ダイ・チェンシアン
リ・ピン
ワン・ジン
リ・スーケー
レイ・ジーガン
チェン・インルー
ソン・シャオレ
Original Assignee
セルラー バイオメディシン グループ （シャンハイ） リミテッド
セルラー バイオメディシン グループ （ウーシー） リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セルラー バイオメディシン グループ （シャンハイ） リミテッド, セルラー バイオメディシン グループ （ウーシー） リミテッド filed Critical セルラー バイオメディシン グループ （シャンハイ） リミテッド
Publication of JP2023516458A publication Critical patent/JP2023516458A/ja
Publication of JP2023516458A5 publication Critical patent/JP2023516458A5/ja
Publication of JPWO2021180237A5 publication Critical patent/JPWO2021180237A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/50—Soluble polymers, e.g. polyethyleneglycol [PEG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
JP2022554328A 2020-03-13 2021-03-15 ヒト細胞由来細胞外小胞を含有する噴霧吸入製剤、その調製方法及び使用 Pending JP2023516458A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010177541.7 2020-03-13
CN202010177541.7A CN113384597A (zh) 2020-03-13 2020-03-13 含人体细胞衍生的细胞膜外囊泡的雾化吸入制剂、制法及其应用
PCT/CN2021/080869 WO2021180237A1 (zh) 2020-03-13 2021-03-15 含人体细胞衍生的细胞膜外囊泡的雾化吸入制剂、制法及其应用

Publications (3)

Publication Number Publication Date
JP2023516458A true JP2023516458A (ja) 2023-04-19
JP2023516458A5 JP2023516458A5 (https=) 2024-03-27
JPWO2021180237A5 JPWO2021180237A5 (https=) 2024-03-27

Family

ID=77616331

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022554328A Pending JP2023516458A (ja) 2020-03-13 2021-03-15 ヒト細胞由来細胞外小胞を含有する噴霧吸入製剤、その調製方法及び使用

Country Status (6)

Country Link
US (1) US20230120324A1 (https=)
EP (1) EP4134105A4 (https=)
JP (1) JP2023516458A (https=)
CN (1) CN113384597A (https=)
AU (1) AU2021234601A1 (https=)
WO (1) WO2021180237A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230050813A1 (en) 2020-01-13 2023-02-16 Carmine Therapeutics Pte. Ltd. Nucleic acid loaded red blood cell extracellular vesicles
CN115212230B (zh) * 2021-04-21 2024-12-27 时比曼生物科技(上海)有限公司 含有干细胞胞外囊泡的药物组合物及其在呼吸道炎症治疗中的应用
CN114306621B (zh) * 2021-12-20 2023-10-20 苏州大学 一种携带核酸药物的细胞外泌体及其制备方法与在免疫治疗中的应用
WO2023123216A1 (zh) * 2021-12-30 2023-07-06 中山大学 囊泡在制备治疗肺部疾病的药物中的应用
CN114480260B (zh) * 2022-01-24 2024-02-09 同济大学 一种成体肺干细胞外泌体及其制备方法和应用
CN114099481B (zh) * 2022-01-28 2022-05-24 深圳湾实验室 雾化吸入型糖皮质激素纳米药物及其制备方法和应用
CN114432341B (zh) * 2022-02-18 2024-02-06 徐州医科大学 一种用于预防和治疗高原肺水肿的间充质干细胞杂化胞外囊泡的制备方法
CN114652703B (zh) * 2022-03-14 2023-07-04 陕西兰医维生物科技有限公司 雾化吸入功能性细胞外囊泡在改善急性肺损伤中的应用
CN115414387A (zh) * 2022-08-12 2022-12-02 四川大学华西医院 一种用于治疗肺纤维化的医疗包
WO2024118073A1 (en) * 2022-11-30 2024-06-06 Carmine Therapeutics Pte. Ltd. Pulmonary delivery of nebulized preparations of red blood cell extracellular vesicles (rbcevs)
US11944742B1 (en) * 2023-06-08 2024-04-02 Microneb Tech Holdings, Inc. Apparatus, methods, and systems for administering a medication to an animal
JP7730003B2 (ja) * 2023-02-10 2025-08-27 中国▲医▼薬大学 細胞外小胞／エクソソーム保存溶液及びその混合溶液
CN119097599B (zh) * 2024-09-09 2025-04-18 北京青藤谷禧干细胞科技研究院有限公司 一种含干细胞外泌体的雾化剂及其制备方法和应用
CN119606929A (zh) * 2024-12-02 2025-03-14 浙江大学 一种基于细胞膜的载核酸药物生物囊泡吸入制剂的制备方法及其产品和应用
CN120284902A (zh) * 2025-04-29 2025-07-11 洛阳市中心医院 一种仿生囊泡制剂及其制备方法与应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014507482A (ja) * 2011-03-11 2014-03-27 チルドレンズ メディカル センター コーポレーション 間葉系幹細胞エキソソームに関連する方法および組成物
JP2016518109A (ja) * 2013-03-13 2016-06-23 ユニバーシティ・オブ・マイアミＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉａｍｉ 細胞培養上清および生体液からの微小胞の単離および精製のための方法
WO2019035880A1 (en) * 2017-08-15 2019-02-21 Children's Medical Center Corporation EXOSOMES OF PURIFIED MESENCHYMAL STEM CELLS AND USES THEREOF
JP2023534524A (ja) * 2020-07-20 2023-08-09 ブレインストーム セル セラペウティクス リミテッド 肺疾患を治療するための方法及び組成物
JP2023535298A (ja) * 2020-07-09 2023-08-17 レメディ セル リミテッド 急性呼吸器炎症状態およびサイトカインストーム症候群を処置する方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5667180B2 (ja) * 2009-07-01 2015-02-12 イオン メディックス インコーポレイテッド 哺乳類の有核細胞に由来するマイクロベシクル及びその用途
US10143709B2 (en) * 2014-05-06 2018-12-04 Indiana University Research And Technology Corporation Use of ASC and ASC-CM to treat ARDS, SARS, and MERS
CN105267240B (zh) * 2014-12-16 2019-05-14 天津医科大学眼科医院 间充质干细胞来源的外泌体的用途
CN105796599A (zh) * 2014-12-29 2016-07-27 西比曼生物科技（上海）有限公司 一种用于治疗哮喘的脂肪间充质祖细胞复合物
EP3270984A4 (en) * 2015-03-16 2019-04-17 Duncan Ross TREATMENT METHOD WITH MEMBRANE-INCLUDED VESICLE
WO2018071677A1 (en) * 2016-10-13 2018-04-19 Vbc Holdings Llc Medical uses of exosomes
CN110072991A (zh) * 2016-10-13 2019-07-30 Vbc控股有限责任公司 来源于发炎的细胞或组织的抗炎外泌体
WO2018109525A1 (en) * 2016-12-14 2018-06-21 Università Degli Studi Di Padova New anti-angiogenic extracellurlar vesicles
CN107137426A (zh) * 2017-05-17 2017-09-08 天津普瑞赛尔生物科技有限公司 含人间充质干细胞外泌体提取物的矽肺病治疗雾化剂及其制备方法
CN109419770A (zh) * 2018-03-07 2019-03-05 厦门艾赛生物科技有限公司 一种间充质干细胞外泌体滴眼液及其制备方法和应用
MA53273A (fr) * 2018-08-10 2021-06-16 Omnispirant Ltd Vésicules extracellulaires pour inhalation
CN109432130A (zh) * 2018-12-20 2019-03-08 中科广聚(北京)生物医学技术中心有限公司 间充质干细胞外泌体在制备预防和治疗放射性肺损伤的药物中的应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014507482A (ja) * 2011-03-11 2014-03-27 チルドレンズ メディカル センター コーポレーション 間葉系幹細胞エキソソームに関連する方法および組成物
JP2016518109A (ja) * 2013-03-13 2016-06-23 ユニバーシティ・オブ・マイアミＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉａｍｉ 細胞培養上清および生体液からの微小胞の単離および精製のための方法
WO2019035880A1 (en) * 2017-08-15 2019-02-21 Children's Medical Center Corporation EXOSOMES OF PURIFIED MESENCHYMAL STEM CELLS AND USES THEREOF
JP2023535298A (ja) * 2020-07-09 2023-08-17 レメディ セル リミテッド 急性呼吸器炎症状態およびサイトカインストーム症候群を処置する方法
JP2023534524A (ja) * 2020-07-20 2023-08-09 ブレインストーム セル セラペウティクス リミテッド 肺疾患を治療するための方法及び組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF CLINICAL MEDICINE, vol. 7, 10, JPN7025000716, 14 October 2018 (2018-10-14), pages 1 - 21, ISSN: 0005665583 *
STEM CELLS TRANSLATIONAL MEDICINE, vol. 9, 1, JPN7025000715, 24 October 2019 (2019-10-24), pages 28 - 38, ISSN: 0005665582 *

Also Published As

Publication number Publication date
EP4134105A1 (en) 2023-02-15
US20230120324A1 (en) 2023-04-20
WO2021180237A1 (zh) 2021-09-16
EP4134105A4 (en) 2024-05-15
AU2021234601A1 (en) 2022-10-06
CN113384597A (zh) 2021-09-14

Similar Documents

Publication Publication Date Title
JP2023516458A (ja) ヒト細胞由来細胞外小胞を含有する噴霧吸入製剤、その調製方法及び使用
Wang et al. Peritoneal M2 macrophage-derived extracellular vesicles as natural multitarget nanotherapeutics to attenuate cytokine storms after severe infections
US20170296626A1 (en) Exosome isolation
RU2715866C2 (ru) Мезенхимальные стромальные клетки для лечения синдрома сепсиса
Wu et al. Neutrophil membrane engineered HucMSC sEVs alleviate cisplatin-induced AKI by enhancing cellular uptake and targeting
CN105861430A (zh) 一种外泌体、外泌体的制备方法及其在制备治疗脓毒症药物或者制剂中的应用
CN111182890A (zh) 用于治疗大疱性表皮松解症的方法和组合物
CN115212230B (zh) 含有干细胞胞外囊泡的药物组合物及其在呼吸道炎症治疗中的应用
CN111670029A (zh) 源自成体干细胞的纳米囊泡及其在靶向治疗中的应用
EP4181935A1 (en) Methods and compositions for treating lung conditions
US20190153383A1 (en) Composition for treating chronic pulmonary disease, comprising exosome derived from thrombin-treated stem cell
WO2021147923A1 (zh) 一种囊泡及其应用
Elashiry et al. Proteomic characterization, biodistribution, and functional studies of immune-therapeutic exosomes: implications for inflammatory lung diseases
US20250268948A1 (en) Compositions and methods for treating post acute sequelae of sars-cov-2 infection (long covid)
US20240247234A1 (en) Off-the-shelf human umbilical cord-derived mesenchymal stem cells and preparation method and use thereof
CN115942952A (zh) 使用来自骨髓来源的间充质干细胞的微囊泡的治疗组合物和方法
CN111904980A (zh) 间充质干细胞与在治疗急性肺损伤、急性呼吸窘迫症或肺纤维化中的用途
HK40082197A (en) Atomized inhalation formulation containing human cell-derived extracellular vesicles, preparation method and use thereof
US20250000798A1 (en) Methods related to megakaryocyte-derived extracellular vesicles
CN117431208A (zh) 一种trim15高表达细胞外囊泡的制备及应用
Ma et al. Umbilical cord mesenchymal‐stem‐cell‐derived nanovesicles as a novel strategy to promote wound healing in diabetes
CN108606981B (zh) 运用MSCs定向趋化特性运载EPO治疗肺纤维化
CN112336871A (zh) 一种用于缓解肺部炎症的DiR-SPIO-ST2纳米颗粒及其制备方法
Xu et al. Effect Analysis of Extracellular Vesicles in the Treatment of Bronchopulmonary Dysplasia via Different Drug Delivery and Administration Routes
EP4252761A2 (en) Composition for treating infectious diseases, comprising exosomes derived from thrombin-treated stem cells

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20231215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240314

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250819